NCT00503685View on ClinicalTrials.gov

Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Colorectal Cancer
Interventions
BIOLOGICAL

IMC-A12

10 milligrams/kilogram (mg/kg) intravenous infusion every 2 weeks.

BIOLOGICAL

cetuximab

Participants will receive cetuximab 500 milligrams/square meter (mg/m²) intravenous over 2 hours every 2 weeks.

Trial Locations (4)

10021

ImClone Investigational Site, New York

14263

ImClone Investigational Site, Buffalo

90095

ImClone Investigational Site, Los Angeles

06520

ImClone Investigational Site, New Haven

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT00503685 - Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy | Biotech Hunter | Biotech Hunter